H. Riska

753 total citations
36 papers, 573 citations indexed

About

H. Riska is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Surgery. According to data from OpenAlex, H. Riska has authored 36 papers receiving a total of 573 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Pulmonary and Respiratory Medicine, 12 papers in Physiology and 6 papers in Surgery. Recurrent topics in H. Riska's work include Inhalation and Respiratory Drug Delivery (8 papers), Asthma and respiratory diseases (8 papers) and Pleural and Pulmonary Diseases (5 papers). H. Riska is often cited by papers focused on Inhalation and Respiratory Drug Delivery (8 papers), Asthma and respiratory diseases (8 papers) and Pleural and Pulmonary Diseases (5 papers). H. Riska collaborates with scholars based in Finland, Denmark and Germany. H. Riska's co-authors include Anne Pietinalho, A B Löfroos, Olof Selroos, Ruth Backman, Matti Klockars, Tom Pettersson, Pia Nyberg, A M Teppo, Thomas Wegener and Ida Steffensen and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Respiratory Journal.

In The Last Decade

H. Riska

33 papers receiving 533 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
H. Riska Finland 14 465 230 83 61 57 36 573
Sumru Beder Türkiye 12 220 0.5× 125 0.5× 62 0.7× 70 1.1× 50 0.9× 28 428
Emel Harmancı Türkiye 11 400 0.9× 104 0.5× 47 0.6× 34 0.6× 18 0.3× 21 527
Michail Toumbis Greece 12 292 0.6× 113 0.5× 57 0.7× 85 1.4× 35 0.6× 22 434
Ryosuke Eda Japan 14 540 1.2× 144 0.6× 42 0.5× 59 1.0× 45 0.8× 27 736
Marlin G. Stahl United States 6 255 0.5× 67 0.3× 64 0.8× 70 1.1× 13 0.2× 7 384
R A Helmers United States 8 866 1.9× 295 1.3× 22 0.3× 106 1.7× 10 0.2× 8 921
Kang Kim South Korea 10 177 0.4× 70 0.3× 22 0.3× 88 1.4× 67 1.2× 21 382
A Pelletier France 7 535 1.2× 97 0.4× 40 0.5× 75 1.2× 14 0.2× 14 647
Deyun Cheng China 13 232 0.5× 144 0.6× 41 0.5× 48 0.8× 56 1.0× 33 437
Sudheer Arava India 11 193 0.4× 60 0.3× 87 1.0× 83 1.4× 82 1.4× 64 465

Countries citing papers authored by H. Riska

Since Specialization
Citations

This map shows the geographic impact of H. Riska's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H. Riska with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H. Riska more than expected).

Fields of papers citing papers by H. Riska

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H. Riska. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H. Riska. The network helps show where H. Riska may publish in the future.

Co-authorship network of co-authors of H. Riska

This figure shows the co-authorship network connecting the top 25 collaborators of H. Riska. A scholar is included among the top collaborators of H. Riska based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with H. Riska. H. Riska is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Reck, Martin, Harry J.M. Groen, H. Riska, et al.. (2006). Initial safety results of an expanded access program (EAP) of erlotinib in non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 24(18_suppl). 7190–7190. 1 indexed citations
4.
Wagenius, Gunnar, Ola Brodin, Jan Nyman, et al.. (2006). Radiotherapy vs. temozolomide in the treatment of patients with lung cancer and brain metastases: A nordic randomized phase II study. Journal of Clinical Oncology. 24(18_suppl). 7136–7136. 4 indexed citations
5.
Anderson, Helén, H. Riska, Serena Knowles, et al.. (2005). Palliative chemotherapy of non-small cell lung cancer (NSCLC): Baseline data analysis of the ACTION observational study in 5 European countries. Journal of Clinical Oncology. 23(16_suppl). 7216–7216. 1 indexed citations
6.
Sørensen, Jakob B., H. Riska, Jesper Ravn, et al.. (2005). Scandinavian phase III trial of neoadjuvant chemotherapy in NSCLC stages IB-IIIA/T3. Journal of Clinical Oncology. 23(16_suppl). 7146–7146. 28 indexed citations
7.
Selroos, Olof, A B Löfroos, Anne Pietinalho, & H. Riska. (2003). Asthma control and steroid doses 5 years after early or delayed introduction of inhaled corticosteroids in asthma: a real-life study. Respiratory Medicine. 98(3). 254–262. 36 indexed citations
8.
Wolff, Henrik, et al.. (2003). Studies of cytokine levels in bronchoalveolar fluid lavage from patients with interstitial lung diseases. Scandinavian Journal of Clinical and Laboratory Investigation. 63(1). 27–36. 10 indexed citations
9.
Pettersson, Tom, et al.. (1999). High pleural fluid hyaluronan concentrations in rheumatoid arthritis. European Respiratory Journal. 13(3). 519–522. 22 indexed citations
10.
Nyberg, Pia, et al.. (1996). Pleural fluid interferon-gamma and tumour necrosis factor-alpha in tuberculous and rheumatoid pleurisy. European Respiratory Journal. 9(8). 1652–1655. 50 indexed citations
11.
Sutinen, S, H. Riska, Ruth Backman, & B Fröseth. (1995). Alveolar lavage fluid (ALF) of normal volunteer subjects: cytologic, immunocytochemical, and biochemical reference values. Respiratory Medicine. 89(2). 85–92. 27 indexed citations
12.
Steffensen, Ida, et al.. (1995). *Inhaled formoterol dry powder in the treatment of patients with reversible obstructive airway disease. Allergy. 50(8). 657–663. 50 indexed citations
13.
14.
Sovijärvi, Anssi, et al.. (1992). Preventive Effects of Inhaled Formoterol and Salbutamol on Histamine-lnduced Bronchoconstriction – A Placebo-Controlled Study. Respiration. 59(5). 279–282. 4 indexed citations
15.
Riska, H., H Tukiainen, Matti Uusitupa, et al.. (1989). COMPARISON OF INTRAVENOUS ENPROFYLLINE AND THEOPHYLLINE IN THE TREATMENT OF ACUTE ASTHMA. Current Therapeutic Research. 45(5). 907–913. 1 indexed citations
16.
Riska, H., et al.. (1986). Comparison of the efficacy of an ACE-inhibitor and a calcium channel blocker in hypertensive asthmatics. A preliminiary report.. PubMed. 62 Suppl 1. 52–3. 9 indexed citations
17.
Riska, H., et al.. (1978). [Exudative pleural effusion].. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 94(8). 490–7.
18.
Riska, H., et al.. (1978). Systemic Lupus Erythematosus and Dna Antibodies in Pleural Effusions. Scandinavian Journal of Rheumatology. 7(3). 159–160. 10 indexed citations
19.
Klockars, Matti, et al.. (1976). Pleural fluid lysozyme in tuberculous and non-tuberculous pleurisy.. BMJ. 1(6022). 1381–1381. 12 indexed citations
20.
Mattson, K., H. Riska, Jari Forsström, & B Kock. (1974). Acute renal failure following rifampicin administration.. PubMed. 55(5). 291–7. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sumru Beder Breakdown of academic impact, for papers by Emel Harmancı Breakdown of academic impact, for papers by Michail Toumbis Breakdown of academic impact, for papers by Ryosuke Eda Breakdown of academic impact, for papers by Marlin G. Stahl Breakdown of academic impact, for papers by R A Helmers Breakdown of academic impact, for papers by Kang Kim Breakdown of academic impact, for papers by A Pelletier Breakdown of academic impact, for papers by Deyun Cheng Breakdown of academic impact, for papers by Sudheer Arava
Rankless by CCL
2026